<?xml version='1.0' encoding='utf-8'?>
<document id="17191263"><sentence text="Venlafaxine induces P-glycoprotein in human Caco-2 cells."><entity charOffset="0-11" id="DDI-PubMed.17191263.s1.e0" text="Venlafaxine" /></sentence><sentence text="The objective of this study was to evaluate the effect of a treatment with venlafaxine on the expression of multidrug resistance-associated protein (MRP) gene and multidrug resistance-related proteins (MDR) in human colon carcinoma cells (Caco-2) compared to a known P-glycoprotein (PGY1) inducer, rifampine"><entity charOffset="75-86" id="DDI-PubMed.17191263.s2.e0" text="venlafaxine" /><entity charOffset="298-307" id="DDI-PubMed.17191263.s2.e1" text="rifampine" /><pair ddi="false" e1="DDI-PubMed.17191263.s2.e0" e2="DDI-PubMed.17191263.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17191263.s2.e0" e2="DDI-PubMed.17191263.s2.e1" /></sentence><sentence text="" /><sentence text="Caco-2 cells were treated with venlafaxine (50 microM, 100 microM, 250 microM, and 500 microM) and rifampin (25 microM and 50 microM) to test the possible induction of MRP and MDR expression"><entity charOffset="31-42" id="DDI-PubMed.17191263.s4.e0" text="venlafaxine" /><entity charOffset="99-107" id="DDI-PubMed.17191263.s4.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.17191263.s4.e0" e2="DDI-PubMed.17191263.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17191263.s4.e0" e2="DDI-PubMed.17191263.s4.e1" /></sentence><sentence text=" The treatment times used were 1" /><sentence text="5, 3, 6, 12, 24, 48, and 72 h" /><sentence text=" RNA was isolated from the cells, and MDR and MRP genes were amplified using PCR" /><sentence text="" /><sentence text="Both venlafaxine and rifampine had the most dramatic effect at the 50 microM concentration"><entity charOffset="5-16" id="DDI-PubMed.17191263.s9.e0" text="venlafaxine" /><entity charOffset="21-30" id="DDI-PubMed.17191263.s9.e1" text="rifampine" /><pair ddi="false" e1="DDI-PubMed.17191263.s9.e0" e2="DDI-PubMed.17191263.s9.e0" /><pair ddi="false" e1="DDI-PubMed.17191263.s9.e0" e2="DDI-PubMed.17191263.s9.e1" /></sentence><sentence text=" There was an increase in MDR and MRP expression in Caco-2 cells after the acute treatment (1" /><sentence text="5, 3, and 6 h) with venlafaxine"><entity charOffset="20-31" id="DDI-PubMed.17191263.s11.e0" text="venlafaxine" /></sentence><sentence text=" These results were similar to those with rifampine"><entity charOffset="42-51" id="DDI-PubMed.17191263.s12.e0" text="rifampine" /></sentence><sentence text="" /><sentence text="PGY1 contributes to renal and biliary elimination of drugs by transporting the drug out of the cell and back into the intestinal lumen, where drugs may be further metabolized by intestinal enzymes such as Cytochrome P (CYP)-450 3A4" /><sentence text=" Its function is to limit the bioavailability of orally administered compounds" /><sentence text=" Due to the increase in MDR and MRP gene expression seen after the acute treatment with venlafaxine, there could be a potential drug-drug interaction with other medications that are metabolized via CYP450-3A4 when coadministered with venlafaxine"><entity charOffset="88-99" id="DDI-PubMed.17191263.s16.e0" text="venlafaxine" /><entity charOffset="234-245" id="DDI-PubMed.17191263.s16.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.17191263.s16.e0" e2="DDI-PubMed.17191263.s16.e0" /><pair ddi="false" e1="DDI-PubMed.17191263.s16.e0" e2="DDI-PubMed.17191263.s16.e1" /></sentence><sentence text="" /></document>